Mumbai, January 21, 2026 Lupin Limited (NSE: LUPIN, BSE: 500257) on Wednesday announced a strategic licensing and supply partnership with Spain based Galenicum Health to expand the reach of injectable Semaglutide across 23 international markets, strengthening its global diabetes and obesity portfolio.
Under the agreement, the collaboration will be executed through Lupin’s subsidiary Lupin Atlantis Holdings SA. Galenicum will be responsible for the development, manufacturing and supply of finished dosage formulations, while Lupin will lead commercialisation, distribution and market expansion across regions including Canada, Europe, Southeast Asia and Latin America.
Semaglutide is a GLP-1 receptor agonist widely prescribed for the management of Type 2 diabetes and for long term weight management in adults with obesity or overweight conditions. The therapy has seen rising global demand amid increasing prevalence of metabolic disorders.
Lupin said the partnership aligns with its strategy to scale its presence beyond India and deepen its footprint in high growth therapeutic segments. The company highlighted that its established commercial infrastructure across multiple international markets positions it well to drive timely launches and broader patient access.
Commenting on the development, Fabrice Egros, President Corporate Development at Lupin, said the agreement represents a key step in strengthening the company’s Semaglutide portfolio and leveraging growth opportunities in the expanding GLP-1 segment. He added that the collaboration supports Lupin’s focus on delivering affordable and high quality medicines to a wider patient base globally.
From Galenicum’s side, co-founder Joaquim Domingo said the partnership is central to the company’s ambition to scale high impact volumes of
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.